CpG depletion results in increased duration of gene expression from plasmid DNA vectors in vivo. (2006)

Lawton, A. E., Davies, L. A., Yew, N. S., Cheng, S. H., Gill, D. R., Hyde, S. C., McLachlan, G. & Collie, D. D. S.

Download   Back

Gene therapy for Cystic Fibrosis lung disease will likely require long-term gene expression; however, in the lung, many gene transfer agents lead to transient gene expression. We have investigated the effects of CpG minimisation on the efficacy and duration of non-viral transgene expression following aerosol delivery of plasmid complexed with 25KDa Polyethylenimine (PEI) to the lungs of BALB/c mice and sheep. A variety of promoter/enhancer sequences were tested in the context of either a standard CpG-rich, or CpG-reduced plasmid backbone. The use of a CMV enhancer/promoter or a CpG-depleted CMV derivative both resulted in transient reporter (luciferase) activity, which fell to background within 7 days irrespective of the CpG status of the plasmid backbone. When the human polyubiquitin (UbC) promoter was tested in the context of a CpG-reduced backbone, luciferase activity was maintained at day 1 levels for at least 28 days (p=0.7459), and up to 56 days in a separate study. Importantly, luciferase expression from the UbC promoter in a CpG-reduced backbone was 10-fold higher than a CpG-rich backbone at day 28 (p=0.0001). To further boost expression levels, hybrid CMV enhancer/polyubiquitin promoters were tested. Iin the context of a CpG-reduced backbone, luciferase activity from the CUCI promoter (CMV enhancer/UbC promoter) in mice was detectable at 28 days post-dose (p=0.0082). Luciferase activity from the CUBI promoter (CMV enhancer/UbB promoter) was five-fold higher than CMV (p=0.0001) in mice. Expression from the CUBI promoter was also seen in the sheep lung at day 1 and was detectable at 8 days post-dose. When delivered to the sheep lung as a DNA/PEI aerosol (n=4), luciferase expression from both the CUCI and CUBI promoters was on average 5- to 10-fold higher than CMV at day 1, with expression still detectable at day 8.

Home
News
Introductory Videos
Medical Futures Innovation Award 2011
Twitter Feed
About Us
Contact Us
Careers
Resources
Lab Events
Environemental Policy
About this Site

Google Site Search

Site Feedback Form

All Site Images

 

UK CFGTC

How the Consortium works/FAQs

Consortium Website

Centre for Molecular Medicine, Edinburgh
The Roslin Institute
Dep of Gene Therapy, Imperial

Milestones

GL67A/pGM169

The Run-in Study

Single Dose Clinical Trial

Multi Dose Clinical Trial

 

Our Research

Non-viral Vector Development

Aerosol Mediated Gene Delivery

Viral Vector Development

Taqman Core Facility

Cystic Fibrosis

History of CF

Discovery of the CFTR Gene

CFTR Protein Structure

CFTR Function

CF Links

 

Gene Therapy

Introduction to Gene Therapy

Other CF Gene Therapy Groups

Why use Gene Therapy for CF

Target Cells for CF Gene Therapy

Barriers for CF Gene Therapy

Clinical Trials

Gene Therapy Successes

Gene Therapy Links

 

 

Publications

Papers in Journals

Conference Posters & Presentations

Book Chapters

D.Phil Theses

Lectures

 

Gene Therapy Seminars

Schedule

Directions & Venue